07/25/2024 | Press release | Distributed by Public on 07/25/2024 15:08
WASHINGTON, D.C. -Today, House Budget Committee Chairman Jodey Arrington (R-TX) and Health Care Task Force (HCTF) Chairman Michael C. Burgess, MD (R-TX) led a bipartisan roundtable entitled, "Threats to Modern Medicine: Examining the Budgetary Effects of Antimicrobial Resistance and the Broken Antibiotic Development Pipeline." Joining in this effort are Rep. Drew Ferguson (R-GA) and Rep. Scott Peters (D-CA) who introduced H.R. 2940, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act to encourage innovative antimicrobial drug development.
Committee members heard from industry experts, including:
Chairman Arrington at the Roundtable:
"We have the best physicians, the best facilities, the best technology, and everybody else has the technology we develop here, but we just can't seem to put it all together. Dr. Burgess is leading the charge to think outside the box, and unleash new ideas for us to examine, leaning on the market forces of innovation, competition, and consumer choice in a way that truly saves lives and creates value for taxpayers. I want to also thank Dr. Ferguson for being the champion on this important issue."
HCTF Chairman Burgess at the Roundtable:
"We are here tasked with safeguarding public health. That is extremely important to us. That's why we're so fortunate to have Drew leading the charge on the PASTEUR Act, to try to make some budgetary sense of the way this country handles antibiotics.
I would far rather practice in a time when antimicrobials are available than a time when they were not available. We're here to explore innovative solutions. Our commitment is to collaborate to curb antimicrobial resistance, and protecting future generations in this crucial endeavor."
Representative Ferguson at the Roundtable:
"We've been investing in AMR for a number of years, and there's some great research being done. But then these innovative companies go bankrupt. Now, we have a bipartisan, bicameral bill moving. It's important for America, and it's important for the world. We want to be the ones solving this problem. We don't want our adversaries solving this problem for us."
Representative Peters at the Roundtable:
"I represent the third largest biotechnology cluster in the country in San Diego. When I talk to companies, I believe in the market as a way to generate solutions for these things. But the market doesn't work here, because the course of treatment is so slow that everyone's getting out of it, you can't induce investment into that risk, with no return. We are trying to figure out a way to make it make sense that people will create new antibiotics. But the other thing I think we're up against is the way we budget. We must be willing to spend some money today to save money later and CBO doesn't always give us that mechanism. The cost is not this year's money. But it's this year's money considering what we get back in future years. That's an institutional problem that we have. We have to deal with this."
Background:
HBC Members pictured from left to right: HCTF Chair Michael Burgess, MD (R-TX), Chairman Jodey Arrington (R-TX), and Rep. Scott Peters (D-CA)
HBC Members pictured from left to right: Rep. Robert Scott (D-VA), Rep. Drew Ferguson (R-GA), and HCTF Chair Michael Burgess, MD (R-TX)
More from the House Budget Committee on Health Care:
Read more on the Health Care Task Force Roundtable titled "Paying for 21st Century Cures: Examining the Budgetary Effects of Increasing Patient Access to Cell and Gene Therapies"HERE.
Read more from Health Care Task Force Chairman Burgess on Cell and Gene Therapies HERE.
Read more on the Health Care Task Force Roundtable Examining the Congressional Budget Office Analysis of Policies that Affect New Medicines Reaching Patients HERE.
Read more on the House Budget Committee hearing examining budgetary effects of growing health care consolidation HERE.